203 related articles for article (PubMed ID: 24853369)
1. The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.
Gingery A; Subramaniam M; Pitel KS; Reese JM; Cicek M; Lindenmaier LB; Ingle JN; Goetz MP; Turner RT; Iwaniec UT; Spelsberg TC; Hawse JR
PLoS One; 2014; 9(5):e98219. PubMed ID: 24853369
[TBL] [Abstract][Full Text] [Related]
2. Skeletal and Uterotrophic Effects of Endoxifen in Female Rats.
Gingery A; Iwaniec UT; Subramaniam M; Turner RT; Pitel KS; McGovern RM; Reid JM; Marler RJ; Ingle JN; Goetz MP; Hawse JR
Endocrinology; 2017 Oct; 158(10):3354-3368. PubMed ID: 28977607
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
4. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract][Full Text] [Related]
5. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
[TBL] [Abstract][Full Text] [Related]
6. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
7. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.
Zhang C; Zhong Q; Zhang Q; Zheng S; Miele L; Wang G
Breast Cancer Res Treat; 2015 Jul; 152(2):283-91. PubMed ID: 26071758
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
10. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
12. A Pharmacokinetic-Pharmacodynamic Model of Tamoxifen and Endoxifen to Predict Their Distribution and Effects on Inhibition of Tumor Growth.
Yuan S; Sun Q; Chen Y; Liao J
Drug Metab Lett; 2017; 11(2):93-101. PubMed ID: 28814243
[TBL] [Abstract][Full Text] [Related]
13. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Sanchez-Spitman AB; Moes DAR; Swen JJ; Dezentjé VO; Lambrechts D; Neven P; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1141-1152. PubMed ID: 32468081
[TBL] [Abstract][Full Text] [Related]
14. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
[TBL] [Abstract][Full Text] [Related]
16. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Lu WJ; Desta Z; Flockhart DA
Breast Cancer Res Treat; 2012 Jan; 131(2):473-81. PubMed ID: 21390495
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
[No Abstract] [Full Text] [Related]
20. Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice.
Chen P; Sheikh S; Ahmad A; Ali SM; Ahmad MU; Ahmad I
Cell Mol Biol Lett; 2018; 23():3. PubMed ID: 29308069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
